Uveitis

Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis

Retrieved on: 
Monday, March 25, 2019
Medical specialties, Medicine, Immunology, RTT, Uveitis, Conjunctivitis, Allergic conjunctivitis, Allergy, Dry eye syndrome

A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com .

Key Points: 
  • A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com .
  • After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.
  • Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.
  • Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjgren-Larsson Syndrome.

Uveitis - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 11, 2019
Health, Pharmaceutical, Uveitis, Drug pipeline, Medical specialties, Medicine, Health

The "Uveitis - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Uveitis - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Uveitis - Pipeline Insight, 2019 offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Uveitis development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Uveitis pipeline products by developmental stage, product type, molecule type, and administration route.

Aldeyra Therapeutics to Host 2019 Research & Development Day

Retrieved on: 
Tuesday, February 12, 2019
Medical specialties, Medicine, Immunology, RTT, Uveitis, Vitreoretinopathy, Allergy, Conjunctivitis, Retinopathy, Medication, Biotechnology, Allergic conjunctivitis

LEXINGTON, Mass., Feb. 12, 2019 /PRNewswire/ --Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra),a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Research & Development Day to provide an update on current late-stage ocular programs.

Key Points: 
  • LEXINGTON, Mass., Feb. 12, 2019 /PRNewswire/ --Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra),a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Research & Development Day to provide an update on current late-stage ocular programs.
  • The presentations will focus on the development and commercialization plans for novel product candidates in proliferative vitreoretinopathy, dry eye disease, allergic conjunctivitis, and noninfectious anterior uveitis.
  • The presentations will begin at 7:30 a.m. Eastern Time on Thursday, February 28, 2019 in New York, New York.
  • Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.

Global Ophthalmic Diagnostic Devices Market 2019-2023 | Increasing Popularity of POC Testing to Augment Growth | Technavio

Retrieved on: 
Thursday, January 10, 2019
Health, Medical devices, Vision, Ophthalmology, Medicine, Uveitis, Fundus photography, Retinitis pigmentosa, Ophthalmic

View the full release here: https://www.businesswire.com/news/home/20190110005419/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190110005419/en/
    Technavio has released a new market research report on the global ophthalmic diagnostic devices market for the period 2019-2023.
  • Ophthalmic diagnostic devices help in detecting ophthalmic diseases such as cataracts, diabetic retinopathy, conjunctivitis, AMD, keratoconus, retinitis pigmentosa, and uveitis.
  • This global ophthalmic diagnostic devices market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
  • Global ophthalmic diagnostic devices market: Segmentation analysis
    This market research report segments the global ophthalmic diagnostic devices market by product (OCT, fundus camera, perimeters, biometers, and others) and geographical regions (APAC, EMEA, and the Americas).

Global Uveitis Market and Competitive Landscape Report 2018-2023 - Develop Tactics and Strategies to Take Advantage of Opportunities in the Market

Retrieved on: 
Friday, November 2, 2018
Economy, Medicine, Uveitis, Business, Market share, Forecasting

The "Global Uveitis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Uveitis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Uveitis Market and Competitive Landscape - 2018, provides comprehensive insights into Uveitis pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • This study accurately estimates and forecast Uveitis market size and drug sales.
  • The research is classified into following sections - Uveitis overview with definitions, symptoms, etiology, diagnosis, treatment options; Uveitis pipeline insights covering late stage clinical trials pipeline; Uveitis prevalence trends by countries; Uveitis market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.